Modular Design of Mesoporous Silica Nanoparticles Enables Bioimaging, Dual Chemotherapy, and Combinatorial Gene Silencing in Triple-Negative Breast Cancer
ACS Applied Materials & Interfaces · 24.12.2025 · 17 (51) · 68925-68938
DOI: 10.1021/acsami.5c15253 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 15.12.2025. Verfasst von Laura P Rebolledo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Silicon Dioxide, Nanoparticles, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancers and remains the most aggressive subtype due to its resistance to standard chemotherapy. A key factor behind its resistance is the activation of antiapoptotic pathways, which help tumor cells evade drug-induced death. We present a modular platform for combinatorial therapy, simultaneously delivering different clinically approved chemotherapeutics and RNAi agents targeting multiple survival pathways in vitro. To ensure that therapeutic activation occurs only after cellular uptake, mesoporous silica nanoparticles were functionalized with cisplatin and gemcitabine via reduction-sensitive linkers, while surface modification with polyethylenimine enabled pH-responsive release of programmable RNA nanoparticles that, upon intracellular dicing, produce DS RNAs targeting the expression of Survivin and BCL-2. This optimized formulation achieved strong gene silencing, minimized immune activation, and enhanced cytotoxicity in TNBC cells compared to either treatment alone. The results highlight the potential of this combinatorial strategy to overcome chemoresistance by delivering multiple therapeutics that simultaneously target distinct survival pathways in cancer cells and can be readily modified and adapted to new targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States.
- Chemistry and Nanoscale Science Program, University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States.
- Center for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States.
ORCID-Profile: Juan L Vivero-Escoto
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
- National Institute of General Medical Sciences
Zitieren
APA
Rebolledo, L. P., Anil Kumar Jeeja, P., Danai, L., Binte Huq, T., Afonin, K. A., & Vivero-Escoto, J. L. (2025). Modular Design of Mesoporous Silica Nanoparticles Enables Bioimaging, Dual Chemotherapy, and Combinatorial Gene Silencing in Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces, 17(51), 68925-68938. https://doi.org/10.1021/acsami.5c15253
Vancouver
Rebolledo LP, Anil Kumar Jeeja P, Danai L, Binte Huq T, Afonin KA, Vivero-Escoto JL. Modular Design of Mesoporous Silica Nanoparticles Enables Bioimaging, Dual Chemotherapy, and Combinatorial Gene Silencing in Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces. 2025;17(51):68925-68938. doi:10.1021/acsami.5c15253
BibTeX
@article{Rebolledo2025,
author = {Rebolledo, Laura P and Anil Kumar Jeeja, Punnya and Danai, Leyla and Binte Huq, Tamanna and Afonin, Kirill A and Vivero-Escoto, Juan L},
title = {Modular Design of Mesoporous Silica Nanoparticles Enables Bioimaging, Dual Chemotherapy, and Combinatorial Gene Silencing in Triple-Negative Breast Cancer},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
volume = {17},
number = {51},
pages = {68925--68938},
doi = {10.1021/acsami.5c15253}
}
EUVIMED